These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38672672)

  • 41. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.
    Haug BH; Henriksen JR; Buechner J; Geerts D; Tømte E; Kogner P; Martinsson T; Flægstad T; Sveinbjørnsson B; Einvik C
    Carcinogenesis; 2011 Jul; 32(7):1005-12. PubMed ID: 21572098
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against
    Bellamy J; Szemes M; Melegh Z; Dallosso A; Kollareddy M; Catchpoole D; Malik K
    Front Oncol; 2020; 10():818. PubMed ID: 32537432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.
    Armstrong MB; Mody RJ; Ellis DC; Hill AB; Erichsen DA; Wechsler DS
    Neoplasia; 2013 Dec; 15(12):1363-70. PubMed ID: 24403858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CCNB1IP1 prevents ubiquitination-mediated destabilization of MYCN and potentiates tumourigenesis of MYCN-amplificated neuroblastoma.
    Zhou Y; Yan H; Zhou Q; Wang P; Yang F; Yuan Z; Du Q; Zhai B
    Clin Transl Med; 2023 Jul; 13(7):e1328. PubMed ID: 37461251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
    Park JH; Szemes M; Vieira GC; Melegh Z; Malik S; Heesom KJ; Von Wallwitz-Freitas L; Greenhough A; Brown KW; Zheng YG; Catchpoole D; Deery MJ; Malik K
    Mol Oncol; 2015 Mar; 9(3):617-27. PubMed ID: 25475372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.
    Li J; Peng J; Wu L; Shen X; Zhen X; Zhang Y; Ma H; Xu Y; Xiong Q; Zhu Q; Zhang P
    J Biol Chem; 2023 Jul; 299(7):104856. PubMed ID: 37230388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MUC15 is an independent prognostic factor that promotes metastases of MYCN non-amplified neuroblastoma.
    Guo H; Zhang WX; Zhang QY; Li M; Wang HY; Li D; Liu J; Zhuo Z; He J; Miao L; Xia H
    J Cancer; 2023; 14(18):3496-3507. PubMed ID: 38021164
    [No Abstract]   [Full Text] [Related]  

  • 48. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FGF represses metastasis of neuroblastoma regulated by MYCN and TGF-β1 induced LMO1 via control of let-7 expression.
    Wang XH; Wu HY; Gao J; Wang XH; Gao TH; Zhang SF
    Brain Res; 2019 Feb; 1704():219-228. PubMed ID: 30321496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.
    Wang SS; Hsiao R; Limpar MM; Lomahan S; Tran TA; Maloney NJ; Ikegaki N; Tang XX
    Int J Mol Med; 2014 Jan; 33(1):35-42. PubMed ID: 24190252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.
    Gu L; Chu P; Lingeman R; McDaniel H; Kechichian S; Hickey RJ; Liu Z; Yuan YC; Sandoval JA; Fields GB; Malkas LH
    EBioMedicine; 2015 Dec; 2(12):1923-31. PubMed ID: 26844271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma.
    Wu PY; Liao YF; Juan HF; Huang HC; Wang BJ; Lu YL; Yu IS; Shih YY; Jeng YM; Hsu WM; Lee H
    PLoS One; 2014; 9(2):e88795. PubMed ID: 24586395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
    Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
    J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
    Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
    Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.
    Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H
    J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma circulating cell-free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma.
    Liang Y; Liu Y; Zhang P; Zhang M; Du B; Cheng W; Yu Z; Li L; Wang H; Hou G; Zhang X; Zhang W
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1688. PubMed ID: 35892165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
    Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
    Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
    [No Abstract]   [Full Text] [Related]  

  • 59. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
    Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
    Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma.
    Sun Q; Chen Y; Jin Q; Yuan X
    Eur J Pediatr; 2022 Dec; 181(12):4135-4147. PubMed ID: 36149505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.